Leighton JK - Search Results

1

Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology.

Saber H, Thompson MD, Leighton JK. Saber H, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2024 May;149:105616. doi: 10.1016/j.yrtph.2024.105616. Epub 2024 Mar 30. Regul Toxicol Pharmacol. 2024. PMID: 38561147

2

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M. Buckley LA, et al. Among authors: leighton jk. Int J Toxicol. 2008 Jul-Aug;27(4):303-12. doi: 10.1080/10915810802367016. Int J Toxicol. 2008. PMID: 18821393

3

Qualification of cardiac troponins for nonclinical use: a regulatory perspective.

Hausner EA, Hicks KA, Leighton JK, Szarfman A, Thompson AM, Harlow P. Hausner EA, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2013 Oct;67(1):108-14. doi: 10.1016/j.yrtph.2013.07.006. Epub 2013 Jul 20. Regul Toxicol Pharmacol. 2013. PMID: 23876748 Review.

4

An FDA oncology analysis of antibody-drug conjugates.

Saber H, Leighton JK. Saber H, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2015 Apr;71(3):444-52. doi: 10.1016/j.yrtph.2015.01.014. Epub 2015 Feb 7. Regul Toxicol Pharmacol. 2015. PMID: 25661711

5

An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.

Leighton JK, Saber H, Reaman G, Pazdur R. Leighton JK, et al. Regul Toxicol Pharmacol. 2016 Aug;79:142-143. doi: 10.1016/j.yrtph.2016.03.001. Epub 2016 Mar 4. Regul Toxicol Pharmacol. 2016. PMID: 26952647 No abstract available.

6

An FDA oncology analysis of immune activating products and first-in-human dose selection.

Saber H, Gudi R, Manning M, Wearne E, Leighton JK. Saber H, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2016 Nov;81:448-456. doi: 10.1016/j.yrtph.2016.10.002. Epub 2016 Oct 13. Regul Toxicol Pharmacol. 2016. PMID: 27743776

7

An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.

Saber H, Del Valle P, Ricks TK, Leighton JK. Saber H, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2017 Nov;90:144-152. doi: 10.1016/j.yrtph.2017.09.001. Epub 2017 Sep 5. Regul Toxicol Pharmacol. 2017. PMID: 28887049 Review.

8

An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates.

Saber H, Simpson N, Ricks TK, Leighton JK. Saber H, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2019 Oct;107:104429. doi: 10.1016/j.yrtph.2019.104429. Epub 2019 Jul 17. Regul Toxicol Pharmacol. 2019. PMID: 31325532

9

An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.

Manning ML, Thompson MD, Saber H, Maher VE, Crich JZ, Leighton JK. Manning ML, et al. Among authors: leighton jk. Regul Toxicol Pharmacol. 2020 Feb;110:104511. doi: 10.1016/j.yrtph.2019.104511. Epub 2019 Oct 31. Regul Toxicol Pharmacol. 2020. PMID: 31678263

10

Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.

Cui W, Rocconi RP, Thota R, Anderson RA, Bruinooge SS, Comstock IA, Denduluri N, Gassman A, Gralow J, Hutt KJ, Amiri-Kordestani L, Lambertini M, Leighton J, Lu KH, Mostoufi-Moab S, Pollastro T, Pradhan S, Saber H, Schenkel C, Spratt D, Wedam S, Phillips KA. Cui W, et al. Lancet Oncol. 2023 Oct;24(10):e415-e423. doi: 10.1016/S1470-2045(23)00390-X. Lancet Oncol. 2023. PMID: 37797647 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters